Literature DB >> 8070029

Using yeast to study resistance to topoisomerase II-targeting drugs.

J L Nitiss1.   

Abstract

We have developed a system utilizing the yeast Saccharomyces cerevisiae to probe the mechanism of action of anti-topoisomerase II drugs. This system has enabled us to dissect the mechanism of action of these agents. By inducing the overexpression of yeast topoisomerase II or by reducing the level of activity using temperature-sensitive mutations in topoisomerase II, we have demonstrated that conversion of topoisomerase II to a cellular poison plays a critical role in cell killing. We have also constructed other mutations in the yeast TOP2 gene that are resistant to etoposide and amsacrine and determined the DNA sequences for several of the drug-resistant alleles. The mutations that confer drug resistance map to several regions of the TOP2 gene. A mutation of particular interest changes Ser741 to Trp. This mutation results in hypersensitivity to etoposide but does not alter sensitivity to other agents such as mAMSA. We suggest that this mutation defines a site on the TOP2 protein that is involved in drug:protein interactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8070029     DOI: 10.1007/bf00684857

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  34 in total

Review 1.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

Review 2.  Topoisomerase-targeting antitumor drugs.

Authors:  P D'Arpa; L F Liu
Journal:  Biochim Biophys Acta       Date:  1989-12-17

3.  The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.

Authors:  M Jannatipour; Y X Liu; J L Nitiss
Journal:  J Biol Chem       Date:  1993-09-05       Impact factor: 5.157

4.  Cloning, characterization, and sequence of the yeast DNA topoisomerase I gene.

Authors:  C Thrash; A T Bankier; B G Barrell; R Sternglanz
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

5.  Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.

Authors:  S H Kaufmann
Journal:  Cancer Res       Date:  1991-02-15       Impact factor: 12.701

6.  A hyper-recombination mutation in S. cerevisiae identifies a novel eukaryotic topoisomerase.

Authors:  J W Wallis; G Chrebet; G Brodsky; M Rolfe; R Rothstein
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

Review 7.  DNA gyrase: structure and function.

Authors:  R J Reece; A Maxwell
Journal:  Crit Rev Biochem Mol Biol       Date:  1991       Impact factor: 8.250

8.  Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

Authors:  B Y Bugg; M K Danks; W T Beck; D P Suttle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

9.  Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.

Authors:  J L Nitiss; Y X Liu; P Harbury; M Jannatipour; R Wasserman; J C Wang
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

10.  Cloning of yeast TOP1, the gene encoding DNA topoisomerase I, and construction of mutants defective in both DNA topoisomerase I and DNA topoisomerase II.

Authors:  T Goto; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

View more
  7 in total

1.  Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.

Authors:  Karin C Nitiss; Mobeen Malik; Xiaoping He; Stephen W White; John L Nitiss
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-02       Impact factor: 11.205

Review 2.  Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.

Authors:  M E Cardenas; M C Cruz; M Del Poeta; N Chung; J R Perfect; J Heitman
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

3.  Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.

Authors:  Ryan P Bender; Michael J Jablonksy; Mohammad Shadid; Ian Romaine; Norma Dunlap; Clemens Anklin; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2008-03-21       Impact factor: 3.162

4.  DNA repair functions that control sensitivity to topoisomerase-targeting drugs.

Authors:  Mobeen Malik; John L Nitiss
Journal:  Eukaryot Cell       Date:  2004-02

5.  Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme.

Authors:  Amy M Wilstermann; Ryan P Bender; Murrell Godfrey; Sungjo Choi; Clemens Anklin; David B Berkowitz; Neil Osheroff; David E Graves
Journal:  Biochemistry       Date:  2007-06-20       Impact factor: 3.162

6.  Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.

Authors:  Anna T Rogojina; John L Nitiss
Journal:  J Biol Chem       Date:  2008-08-22       Impact factor: 5.157

7.  mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.

Authors:  Kathryn L Gilroy; Chrysoula Leontiou; Kay Padget; Jeremy H Lakey; Caroline A Austin
Journal:  Nucleic Acids Res       Date:  2006-03-20       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.